Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib and Romidepsin in Relapsed/Refractory PTCL
NCT03547700Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib, romidepsin in peripheral T-cell lymphoma (PTCL), sponsored by University of Michigan Rogel Cancer Center. Started Sep 2018; status: terminated.
02
Drugs
ixazomibromidepsin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03547700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547700.